Typically, preeclampsia occurs in the 2nd or 3rd trimester or pregnancy. The test, however, measures a specific protein in maternal blood earlier so that physicians can better assess and monitor the condition as the pregnancy progresses.
A prospective cohort of singleton pregnancies underwent routine 1st trimester screening from 2009–2011 (n=5,759). A regression-based predictive model for early- and late-onset preeclampsia was created based on several factors, including levels of pregnancy-associated plasma protein-A and free beta-human chorionic gonadotropin at 8–12 weeks.
Results showed that at 5% and 10% false-positive rates, detection rates were 69.2% and 80.8% for early preeclampsia (AUC 0.95; 95% CI: 0.94–0.98), and 29.4% and 39.6% for late preeclampsia (AUC 0.71; 95% CI: 0.66–0.76), respectively.
The company plans to make the test available in early 2015.
For more information call (877) 748-9355 or visit DiabetOmics.com.